Responsive image

Common name


N'-benzylacetohydrazide

IUPAC name


N'-benzylacetohydrazide

SMILES


C(c1ccccc1)NNC(=O)C

Common name


N'-benzylacetohydrazide

IUPAC name


N'-benzylacetohydrazide

SMILES


C(c1ccccc1)NNC(=O)C

INCHI


InChI=1S/C9H12N2O/c1-8(12)11-10-7-9-5-3-2-4-6-9/h2-6,10H,7H2,1H3,(H,11,12)

FORMULA


C9H12N2O

Responsive image

Common name


N'-benzylacetohydrazide

IUPAC name


N'-benzylacetohydrazide





Molecular weight


164.204

clogP


0.926

clogS


-2.475

Frequency


0.0003





HBond Acceptor


1

HBond Donor


2

Total Polar
Surface Area


41.13

Number of Rings


1

Rotatable Bond


3

Drug ID Common name Structure CAS Compound class Therapeutic area
FDBD00923 Atazanavir Responsive image Anti-HIV Agents; Protease Inhibitors; HIV Protease Inhibitors; Antiinfectives for Systemic Use; Direct Acting Antivirals; Antivirals for Systemic Use; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C9 Inducers; CYP3A4 Inhibitors; Combined Inhibitors of CYP3A4 and P-glycoprotein; Used in combination with other antiretroviral agents for the treatment of HIV-1 infection, as well as postexposure prophylaxis of HIV infection in individuals who have had occupational or nonoccupational exposure to potentially infectious body fluids of a person known to be infected with HIV when that exposure represents a substantial risk for HIV transmission.
1 , 1
FRAGNAME PDBID SIMILIRITY XSCORE SMILE HAC
3mlb_ligand_3_82.mol2 3mlb 1 -7.41 C(NNC(=O)C)c1ccccc1 12
2cen_ligand_4_460.mol2 2cen 1 -6.69 [NH2+](NC(=O)C)Cc1ccccc1 12
2bqv_ligand_4_147.mol2 2bqv 1 -6.66 CC(=O)N[NH2+]Cc1ccccc1 12
2cem_ligand_4_460.mol2 2cem 1 -6.63 C([NH2+]NC(=O)C)c1ccccc1 12
2wkz_ligand_4_700.mol2 2wkz 1 -6.62 [NH2+](NC(=O)C)Cc1ccccc1 12
2o4k_ligand_4_1787.mol2 2o4k 1 -6.50 N(C(=O)C)[NH2+]Cc1ccccc1 12
3ekw_ligand_4_1787.mol2 3ekw 1 -6.47 C(c1ccccc1)[NH2+]NC(=O)C 12
2wl0_ligand_4_700.mol2 2wl0 1 -6.46 c1(ccccc1)C[NH2+]NC(=O)C 12
3eky_ligand_4_1787.mol2 3eky 1 -6.43 [NH2+](Cc1ccccc1)NC(=O)C 12
100 , 11